Alkermes (ALKS) Started Phase 3 Trials For Alixorexton In Narcolepsy Type 1

• Alkermes (NasdaqGS: ALKS) reported positive phase 2 results for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1, and announced the start of global phase 3 trials.
• The phase 2 study publication highlighted efficacy on key narcolepsy symptoms along with a favorable tolerability profile.
• Alixorexton has received Breakthrough Therapy and Orphan Drug designations, which could influence its regulatory path and commercial potential in narcolepsy.

For readers looking at Alkermes and wanting more under-the-radar ideas in similar areas, the next logical step is to review our screener containing 21 high quality undiscovered gems.

Alkermes, a US based biopharmaceutical company with a market cap of about $8.0b, focuses on developing medicines for unmet medical needs across multiple therapeutic areas. Alixorexton fits into that broader research effort as the company looks to expand its neurology and sleep disorder portfolio internationally.

Beyond the headline: 3 risks and 2 things going right for Alkermes that every investor should see.

How important is alixorexton’s phase 2 profile for Alkermes’ market opportunity?

The Vibrance-1 data show that alixorexton reached normative ranges on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale across all tested doses and reduced weekly cataplexy rate at 6 mg. For investors this points to a product profile that targets core narcolepsy symptoms, which is central to competing for NT1 and potentially NT2 patients.

Does this change the Alkermes Narrative around long term growth drivers?

This update directly supports the existing Narrative that orexin agonist data help de risk Alkermes’ long term R&D strategy and open up additional disorders beyond narcolepsy. It also connects to the risk that rising R&D spend on these late stage trials needs to be justified by successful registration and commercialization.

If we take a look at the community Narrative for Alkermes, we can see how this news fits into the bigger investment story.

What should investors watch next to see if alixorexton is on track?

The clearest signal will be how the phase 3 Brilliance studies in NT1 and NT2 progress. Key points will include whether they hit the same endpoints as Vibrance on MWT, ESS and cataplexy over longer treatment. Any updates on trial timelines, enrollment status or interim safety data will be important markers.

For the full picture including more risks and rewards, check out the complete Alkermes analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com